Xenical and Orlistat in the Philippines

Nearly every other weight-loss drug in the Philippine market acts on appetite. Phentermine, sold here as Duromine, works on central noradrenergic signalling. The GLP-1 receptor agonists work through gut hormone signalling that reaches the brain and slows gastric emptying. Orlistat does none of that. It never meaningfully leaves the gastrointestinal tract, and it has nothing at all to say about how hungry you feel.

What it does is inhibit gastric and pancreatic lipase, the enzymes that split dietary triglycerides into absorbable free fatty acids and monoglycerides. An orlistat molecule binds covalently to the active serine site on those enzymes and takes them out of service. Fat that is never split is never absorbed across the intestinal wall. The Xenical label states that at the recommended 120mg three times daily, orlistat inhibits dietary fat absorption by approximately 30%.

Three consequences follow directly from that mechanism, and they explain almost everything else about the drug.

The effect is proportional to what you eat. Orlistat has nothing to block in a meal of rice, pandesal and soft drink. On a typical Filipino diet that leans heavily on carbohydrate rather than fat, the absolute number of calories blocked can be modest even when the drug is taken exactly as directed.

The blocked fat has to leave the body. Undigested triglyceride passes into the colon and exits as oil. That is not a side effect in the usual sense of an off-target reaction. It is the mechanism, observed from the other end.

Anything that rides in on dietary fat is affected too. Vitamins A, D, E and K are fat soluble, and reducing fat absorption reduces theirs. That is covered further down.

Orlistat 120mg is registered with FDA Philippines and dispensed on prescription. In the chains it appears in three forms: branded Xenical, the chain generic sold as Watsons Generics orlistat, and Lesofat, a locally familiar orlistat brand. All three are the same molecule at the same strength. Watsons sells all three sold per piece, which is how a large share of Filipino buyers actually purchase medicine, capsule by capsule as cash allows.

Alli is different, and this is the single most misunderstood point in the category. Alli is orlistat 60mg, half the prescription strength, approved as an over-the-counter product in the United States. It has no Philippine registration. No Philippine pharmacy stocks it lawfully, and it is not the cheaper local option that overseas articles imply it is. It reaches Filipino buyers only through personal import, mainly iHerb and Ubuy, at import pricing.

The figures below were taken from live Watsons Philippines product pages in August 2026. Philippine pharmacy pricing moves, and branch pricing can differ from online listings, so treat these as dated reference points rather than quotes.

Two things in that table are worth pausing on. The first is the spread: branded Xenical is roughly double the chain generic for the same 120mg of the same molecule. The second is that the 8+2 pack works out dearer per capsule than buying the same generic loose, which is the opposite of what a shopper reasonably assumes a multipack does. Check the per-capsule figure rather than the pack price.

Mercury Drug, the other chain most Filipino buyers check first, does not publish medicine prices online. It runs a price enquiry form instead, so Mercury pricing has to be confirmed at a branch or by phone. Anyone quoting you a precise Mercury peso figure from a blog is quoting something they did not verify. MedsGo carries orlistat listings as well, and its per-capsule display is inconsistent enough that we would not build a budget on it without confirming in a branch.

Per-capsule pricing hides the real number, because orlistat is dosed with each main meal containing fat. Three capsules a day is the standard pattern, which is about 90 capsules in a month. Run that through the verified per-capsule figures and the picture changes.

So the honest range for a full month of orlistat in the Philippines runs from roughly ₱2,200 on the chain generic to roughly ₱4,600 on branded Xenical, plus the multivitamin the label asks for and the cost of the consultation that produced the prescription. That arithmetic is illustrative, not a quotation: it assumes three capsules every day, and in practice people skip the dose at a low-fat meal, which is what the label allows.

Set against injectables, that is genuinely cheap. Manila Bulletin reported in June 2026 that Ozempic pricing in the Philippines had climbed from about ₱6,200 to over ₱8,700 a pen amid shortage, with some sellers above ₱11,000. A month of generic orlistat costs less than a quarter of one pen at those levels. The full comparison sits in the GLP-1 price index and the Ozempic pricing filing. What that cheapness buys you is the subject of the efficacy section below, and the answer is not proportional.

The two products are the same drug at different strengths, sold under different regulatory regimes. Alli is orlistat 60mg, sold over the counter overseas on the reasoning that a half-strength dose is safe enough to self-select. Xenical is orlistat 120mg, prescription everywhere including here. Alli produces a smaller effect than the 120mg dose, which is the trade for its over-the-counter status.

That last row is the whole argument. The iHerb Philippines listing for the Alli 60-capsule starter pack showed ₱5,531.79 when checked in August 2026, which is 3,600mg of orlistat. The Watsons chain generic delivers 120mg for ₱24.68. Per milligram of active drug, the import route costs roughly seven times more than the registered product sitting in a Philippine pharmacy, before you count shipping time or the risk of the parcel being held.

There is a second problem underneath the arithmetic. Because Alli has no Philippine registration, a parcel of it is an unregistered drug product on arrival. Personal-quantity imports of this kind are commonly tolerated, but tolerance is not a right, and there is no local recourse if the shipment is detained or if what arrives is not what was ordered. Buyers reach for Alli because they read about it in overseas coverage and assume it is the entry-level option. In the Philippines it is the expensive, unprotected one.

Orlistat works. It works less than the marketing around it has ever implied, and far less than what has arrived in the last five years. The published figures are not ambiguous and it is worth reading them plainly.

A benefit-risk assessment of orlistat put the placebo-subtracted reduction in body weight at around 3kg at one year. The four-year XENDOS trial, which remains the longest good look at the drug, found the orlistat group down 10.6kg at one year against 6.2kg on placebo, with both groups on the same lifestyle programme. By year four the two arms had converged to 5.8kg against 3.0kg. XENDOS also recorded a 37.3% relative reduction in the incidence of type 2 diabetes over four years, which is a real and underdiscussed result, and arguably the strongest thing on orlistat's record.

These are separate trials with different populations, endpoints and eras of trial design. Reading them side by side gives you the order of magnitude, not a like-for-like ranking.

The gap is not subtle. Orlistat delivers a few kilograms on top of diet. Current GLP-1 and dual-agonist trials report percentage losses in the teens and low twenties. Anyone deciding between them should understand that they are not near substitutes, and that the price difference is tracking a real difference in effect rather than a branding premium. What orlistat has going for it is availability, a very long safety record, a mechanism confined to the gut, and a cost that a Filipino household can actually carry month after month. That combination is not nothing. Compare with what else is realistically on the table in the alternatives filing and the weight-loss peptides overview.

This is the part most Philippine retail listings omit entirely, and it is the one genuinely avoidable risk in taking orlistat.

Vitamins A, D, E and K are absorbed alongside dietary fat. Block a portion of fat absorption and you reduce theirs. The Xenical label states plainly that the drug has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene, and it instructs patients to take a multivitamin containing those vitamins at least two hours before or after a dose, giving bedtime as the practical way to do it.

Two hours is the operative detail. A multivitamin swallowed with the same glass of water as the capsule is largely wasted, because the lipase inhibition is working on the contents of that meal. The label solves the timing problem by suggesting bedtime, which sits clear of the three meal-time doses.

Longer courses raise the stakes. Someone taking orlistat for six weeks and stopping is in a different position from someone taking it for two years, and vitamin D status in particular is worth a conversation with your doctor if the course is going to be long. Guidance on how to raise that is the same as for any long-running weight intervention, covered in general terms in the side effects filing.

Orlistat is not a dangerous drug. It is a socially difficult one, and that distinction is what actually determines whether it works for a given person.

The Xenical label reports, for year one of treatment, oily spotting in 26.6% of patients, flatus with discharge in 23.9%, faecal urgency in 22.1%, fatty or oily stool in 20.0% and oily evacuation in 11.9%. The label characterises these as generally mild and transient, decreasing in the second year of treatment. Both halves of that sentence are true and both matter. These are not organ-level harms. They are also, for someone commuting an hour and a half into Makati or working a shift with fixed break times, a serious practical problem.

Here is the mechanism turning back on itself. The effects scale with how much fat you eat, so the drug functions as an immediate and unmistakable feedback signal about the previous meal. Some clinicians consider that behaviourally useful, and there is something to it: lechon kawali has a consequence you feel the same day. But the same feedback loop produces the failure mode that defines the drug in practice. People do not stop orlistat because it stops working. They stop because they cannot plan a working day around it.

None of those are irrational responses. They are what a person does when a drug imposes a cost at an inconvenient moment. It is worth being honest with yourself before starting: the trial figures above come from people who kept taking it, and the middle two rows of that table quietly convert the drug into a much weaker version of itself. Whether that trade suits your work, your commute and your diet is a real part of the decision, and it belongs in the conversation with your physician alongside the clinical questions.